文献速递神经眼科

信使核糖核酸2019冠状病毒病疫苗接种后视神经炎风险与2019冠状病毒病感染及其他疫苗接种的比较

The Risk of Optic Neuritis following mRNA Coronavirus Disease 2019 Vaccination Compared to Coronavirus Disease 2019 Infection and Other Vaccinations.
PubMed 文献 · Ophthalmology · 2024-02-24

基于美国全国聚合数据库的回顾性队列研究,比较信使核糖核酸2019冠状病毒病疫苗、流感疫苗、破伤风-白喉-百日咳联合疫苗及未接种且感染2019冠状病毒病人群的视神经炎风险。结果显示接种信使核糖核酸2019冠状病毒病疫苗后视神经炎罕见,与破伤风-白喉-百日咳联合疫苗相当,低于流感疫苗和2019冠状病毒病感染。

要点

  • 接种信使核糖核酸2019冠状病毒病疫苗后21天内视神经炎风险为每10万人中1例。
  • 信使核糖核酸2019冠状病毒病疫苗首剂与流感疫苗相比,视神经炎风险比0.44(95%CI 0.28-0.80)。
  • 信使核糖核酸2019冠状病毒病疫苗接种者与未接种且感染2019冠状病毒病者相比,视神经炎风险比0.09(95%CI 0.07-0.12)。

核心结论

  • 接种信使核糖核酸2019冠状病毒病疫苗后发生视神经炎的风险罕见,与破伤风-白喉-百日咳联合疫苗接种后风险相当,低于流感疫苗接种后风险,也低于未接种疫苗情况下2019冠状病毒病感染后的风险。

研究设计与样本

  • 美国全国聚合数据库回顾性队列研究。
  • 依据2020年12月至2022年6月期间信使核糖核酸2019冠状病毒病疫苗接种状态(未接种且有2019冠状病毒病感染史、接种1剂、接种2剂)划分队列。
  • 设置两个对照队列:2018年6月至2019年12月期间接种流感疫苗或破伤风-白喉-百日咳联合疫苗的患者。
  • 排除有视神经炎病史或存在视神经炎发生重要危险因素(包括感染性、炎症性和肿瘤性疾病)的患者。
  • 队列按年龄、性别、种族和民族进行1:1倾向评分匹配。

主要发现

  • 信使核糖核酸2019冠状病毒病疫苗首剂队列与流感疫苗队列(n=1 678 598,接种时平均年龄[标准差]分别为45.5[23.3]岁和43.2[25.5]岁,女性55%)比较,发生视神经炎的风险比为0.44(95%CI 0.28-0.80)。
  • 信使核糖核酸2019冠状病毒病疫苗首剂与破伤风-白喉-百日咳联合疫苗队列(n=797 538,平均年龄38.9[20.0]岁,女性54.2%)比较,分别有10例和16例患者发生视神经炎(风险比0.63;95%CI 0.28-1.38)。
  • 接种信使核糖核酸2019冠状病毒病疫苗的患者(n=3 698 848,平均年龄48.2[21.5]岁,女性54.7%)与未接种且感染2019冠状病毒病的患者(n=3 698 848,平均年龄49.6[22.0]岁,女性55.2%)比较,分别有49例和506例患者发生视神经炎(风险比0.09;95%CI 0.07-0.12)。
  • 每10万人中视神经炎发病率:信使核糖核酸2019冠状病毒病疫苗首剂队列为1例,流感疫苗队列为2例,破伤风-白喉-百日咳联合疫苗队列为2例,2019冠状病毒病感染且未接种队列为14例。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine the risk of optic neuritis (ON) after mRNA Coronavirus Disease 2019 (COVID-19) vaccine administration. DESIGN: U.S. National aggregate database retrospective cohort study. PARTICIPANTS: Patients were placed into cohorts based on mRNA COVID-19 vaccination status (no vaccine and positive history of COVID-19 infection, 1 vaccine, or 2 vaccines received) from December 2020 to June 2022. Two control cohorts were created with patients vaccinated against influenza or tetanus, diphtheria, and pertussis (Tdap) from June 2018 to December 2019. Patients with any history of ON or significant risk factors for ON development including infectious, inflammatory, and neoplastic diseases were excluded. METHODS: A large deidentified database was queried for the Common Procedural Technology codes for immunization encounters specific to first dose and second dose of mRNA COVID-19 vaccine, influenza, or Tdap. Cohorts were 1:1 propensity score matched on age, sex, race, and ethnicity. The risk of ON development after vaccination was calculated and compared for all 5 cohorts with 95% confidence intervals (CIs) reported. MAIN OUTCOME MEASURES: Risk ratio (RR) of ON 21 days after vaccination (or COVID-19 infection) and incidence of ON per 100 000 individuals. RESULTS: After matching, the first dose COVID-19 and influenza vaccine cohorts (n = 1 678 598, mean age [standard deviation] at vaccination of 45.5 [23.3] years and 43.2 [25.5] years, 55% female) the RR of developing ON was 0.44 (95% CI, 0.28-0.80). The first dose of COVID-19 and Tdap vaccinations (n = 797 538, mean age 38.9 [20.0] years, 54.2% female) cohort had 10 and 16 patients develop ON (RR, 0.63; 95% CI, 0.28-1.38). Comparison of COVID-19-vaccinated patients (n = 3 698 848, 48.2 [21.5] years, 54.7% female) to unvaccinated and COVID-19-infected patients (n = 3 698 848, 49.6 [22.0] years, 55.2% female) showed 49 and 506 patients developing ON, respectively (RR, 0.09; 95% CI, 0.07-0.12). The incidence per 100 000 for ON was 1 in the first dose COVID-19 vaccine cohort, 2 in the influenza cohort, and 2 in the Tdap cohort, and 14 in the COVID-19-infected and unvaccinated cohorts. CONCLUSIONS: Risk of ON after mRNA COVID-19 vaccination is rare and comparable to Tdap vaccination, decreased compared with influenza vaccination, and decreased compared with COVID-19 infection in the absence of vaccination. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Shukla P, Sharma N, Shaia JK, et al. The Risk of Optic Neuritis following mRNA Coronavirus Disease 2019 Vaccination Compared to Coronavirus Disease 2019 Infection and Other Vaccinations. Ophthalmology. 2024. PMID: 38408705. doi:10.1016/j.ophtha.2024.02.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。